Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma (IDARA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03757221

Recruitment Status : Recruiting

First Posted : November 28, 2018

Last Update Posted : July 8, 2019

See Contacts and Locations

Sponsor:

Information provided by (Responsible Party):

University Hospital, Caen

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Recruiting
Estimated Primary Completion Date :	December 31, 2024
Estimated Study Completion Date :	December 31, 2025

To Top